Patents by Inventor Tamara Maes

Tamara Maes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combinations of LSD1 inhibitors for use in the treatment of solid tumors
    Patent number: 12564559
    Abstract: The instant invention relates to therapeutic combinations of LSD1 inhibitors and one or more other active pharmaceutical ingredient(s) or pharmaceutically acceptable salts thereof. The combinations are particularly useful for treating neoplastic diseases, such as cancer, particularly small cell lung cancer (SCLC).
    Type: Grant
    Filed: May 4, 2022
    Date of Patent: March 3, 2026
    Assignee: ORYZON GENOMICS, S.A.
    Inventors: Mark D. Demario, Tamara Maes, William E. Pierceall, Fiona Mack, Serena Lunardi
  • COMBINATIONS OF LSD1 INHIBITORS FOR TREATING MYELOID CANCERS
    Publication number: 20250073232
    Abstract: The instant invention relates to combinations of LSD1 inhibitors (or pharmaceutically acceptable salts thereof) and gilteritinib (or a pharmaceutically acceptable salt thereof). The combinations are particularly useful for treating myeloid cancers, such as acute myeloid leukemia or myelodysplastic syndrome.
    Type: Application
    Filed: March 21, 2022
    Publication date: March 6, 2025
    Inventors: Tamara MAES, Natalia SACILOTTO
  • Methods to determine KDM1A target engagement and chemoprobes useful therefor
    Patent number: 12195783
    Abstract: The invention relates to methods to determine KDM1A target engagement and chemoprobes useful therefor. In particular, the invention relates to non-peptidic KDM1A chemoprobes carrying a tag or label that can be used to assess KDM1A target engagement in cells and tissues. These chemoprobes can also be used to identify KDM1A interacting factors and analyze expression levels of KDM1A.
    Type: Grant
    Filed: December 16, 2021
    Date of Patent: January 14, 2025
    Assignee: Oryzon Genomics S.A.
    Inventors: Elena Carceller González, Tamara Maes, Cristina Mascaro Crusat, Alberto Ortega Muñoz
  • METHODS OF TREATING BEHAVIOR ALTERATIONS
    Publication number: 20240277673
    Abstract: Provided herein are methods for treating behavior alterations using KDM1A inhibitors, particularly 5-((((1R,2S)-2-(4-(benzyloxy)phenyl)cyclopropyl)amino)methyl)-1,3,4-oxadiazol-2-amine.
    Type: Application
    Filed: August 18, 2023
    Publication date: August 22, 2024
    Inventors: Tamara MAES, David ROTLLANT POZO, Christian GRIÑÁN FERRE, Mercè PALLÀSLLIBERIA, Roser NADAL ALEMANY, Antonio ARMARIO GARCÍA
  • METHODS TO DETERMINE KDM1A TARGET ENGAGEMENT AND CHEMOPROBES USEFUL THEREFOR
    Publication number: 20220389478
    Abstract: The invention relates to methods to determine KDM1A target engagement and chemoprobes useful therefor. In particular, the invention relates to non-peptidic KDM1A chemoprobes carrying a tag or label that can be used to assess KDM1A target engagement in cells and tissues. These chemoprobes can also be used to identify KDM1A interacting factors and analyze expression levels of KDM1A.
    Type: Application
    Filed: December 16, 2021
    Publication date: December 8, 2022
    Inventors: Elena CARCELLER GONZÁLEZ, Tamara MAES, Cristina MASCARO CRUSAT, Alberto ORTEGA MUÑOZ
  • COMBINATIONS OF LSD1 INHIBITORS FOR USE IN THE TREATMENT OF SOLID TUMORS
    Publication number: 20220378722
    Abstract: The instant invention relates to therapeutic combinations of LSD1 inhibitors and one or more other active pharmaceutical ingredient(s) or pharmaceutically acceptable salts thereof. The combinations are particularly useful for treating neoplastic diseases, such as cancer, particularly small cell lung cancer (SCLC).
    Type: Application
    Filed: May 4, 2022
    Publication date: December 1, 2022
    Inventors: Mark D. DEMARIO, Tamara MAES, William E. PIERCEALL, Fiona MACK, Serena LUNARDI
  • COMBINATIONS OF LSD1 INHIBITORS FOR THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES
    Publication number: 20220331265
    Abstract: The instant invention relates to combinations of the compound of formula (I) or pharmaceutically acceptable salts thereof with other active pharmaceutical ingredients (I), pharmaceutical compositions comprising them, and their use as medicaments, particularly for the treatment of hematological malignancies.
    Type: Application
    Filed: November 19, 2021
    Publication date: October 20, 2022
    Inventors: Filippo CICERI, Serena LUNARDI, Tamara MAES, Cristina MASCARO CRUSAT, Inigo TIRAPU FERNANDEZ DE LA CUESTA
  • Methods to determine KDM1A target engagement and chemoprobes useful therefor
    Patent number: 11034991
    Abstract: The invention relates to methods to determine KDM1A target engagement and chemoprobes useful therefor. In particular, the invention relates to non-peptidic KDM1A chemoprobes carrying a tag or label that can be used to assess KDM1A target engagement in cells and tissues. These chemoprobes can also be used to identify KDM1A interacting factors and analyze expression levels of KDM1A.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: June 15, 2021
    Assignee: Oryzon Genomics S.A.
    Inventors: Elena Carceller González, Tamara Maes, Cristina Mascaro Crusat, Alberto Ortega Muñoz
  • Combinations of LSD1 inhibitors for the treatment of hematological malignancies
    Patent number: 11013698
    Abstract: The instant invention relates to combinations of the compound of formula (I) or pharmaceutically acceptable salts thereof with other active pharmaceutical ingredients pharmaceutical compositions comprising them, and their use as medicaments, particularly for the treatment of hematological malignancies.
    Type: Grant
    Filed: March 13, 2017
    Date of Patent: May 25, 2021
    Assignee: Oryzon Genomics S.A.
    Inventors: Filippo Ciceri, Serena Lunardi, Tamara Maes, Cristina Mascaro Crusat, Inigo Tirapu Fernandez De La Cuesta
  • METHODS OF TREATING BEHAVIOR ALTERATIONS
    Publication number: 20200323828
    Abstract: Provided herein are methods for treating behavior alterations using KDM1A inhibitors, particularly 5-((((1R,2S)-2-(4-(benzyloxy)phenyl)cyclopropyl)amino)methyl)-1,3,4-oxadiazol-2-amine.
    Type: Application
    Filed: August 3, 2018
    Publication date: October 15, 2020
    Inventors: Tamara MAES, David ROTLLANT POZO, Christian GRIÑÁN FERRE, Mercè PALLÀS LLIBERIA, Roser NADAL ALEMANY, Antonio ARMARIO GARCÍA
  • Method of treating multiple sclerosis employing a LSD1-inhibitor
    Patent number: 10780081
    Abstract: Provided herein are methods for treating multiple sclerosis using (?) 5-((((trans)-2-(4-(benzyloxy)phenyl)cyclopropyl)amino)methyl)-1,3,4-oxadiazol-2-amine, or a pharmaceutically acceptable salt or solvate thereof.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: September 22, 2020
    Assignee: Oryzon Genomics, S.A.
    Inventors: Tamara Maes, Cristina Mascarò Crusat, David Rotllant Pozo
  • BIOMARKERS FOR DETERMINING RESPONSIVENESS TO LSD1 INHIBITORS
    Publication number: 20190256930
    Abstract: The present invention relates to methods for monitoring the response to treatment with an LSD1 inhibitor in a subject suffering from leukemia. The present invention also provides methods for the identification of a responding subject to treatment with an LSD1 inhibitor. Also methods of determining whether a proliferative diseased cell is responsive to treatment with an LSD1 inhibitor are provided. The methods comprise determining the level of one or more of markers in a sample, wherein an increased level of one or more of said markers compared to a control indicates responsiveness to the LSD1 inhibitor. Methods of treatment of patients with the LSD1 inhibitor, wherein the patients are identified in accordance with the present invention to be responders are also subject of the present invention. LSD1 inhibitors for use in the treatment of this patient group are provided.
    Type: Application
    Filed: November 2, 2017
    Publication date: August 22, 2019
    Inventors: Maria Isabel ARÉVALO SÁNCHEZ, Serena LUNARDI, Tamara MAES, Cristina MASCARO CRUSAT
  • Combinations of LSD1 inhibitors for use in the treatment of solid tumors
    Patent number: 10265279
    Abstract: The instant invention relates to therapeutic combinations of LSD1 inhibitors and one or more other active pharmaceutical ingredient(s) or pharmaceutically acceptable salts thereof. The combinations are particularly useful for treating neoplastic diseases, such as cancer, particularly small cell lung cancer (SCLC).
    Type: Grant
    Filed: March 14, 2017
    Date of Patent: April 23, 2019
    Assignee: Oryzon Genomics, S.A.
    Inventors: Mark D. Demario, Tamara Maes, William E. Pierceall, Fiona Mack, Serena Lunardi
  • METHOD OF TREATING MULTIPLE SCHLEROSIS EMPLOYING A LSD1-INHIBITOR
    Publication number: 20190083469
    Abstract: Provided herein are methods for treating multiple sclerosis using (?) 5-((((trans)-2-(4-(benzyloxy)phenyl)cyclopropyl)amino)methyl)-1,3,4-oxadiazol-2-amine, or a pharmaceutically acceptable salt or solvate thereof.
    Type: Application
    Filed: June 9, 2017
    Publication date: March 21, 2019
    Inventors: Tamara MAES, Cristina MASCARÒ CRUSAT, David ROTLLANT POZO
  • COMBINATIONS OF LSD1 INHIBITORS FOR THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES
    Publication number: 20190083417
    Abstract: The instant invention relates to combinations of the compound of formula (I) or pharmaceutically acceptable salts thereof with other active pharmaceutical ingredients pharmaceutical compositions comprising them, and their use as medicaments, particularly for the treatment of hematological malignancies.
    Type: Application
    Filed: March 13, 2017
    Publication date: March 21, 2019
    Inventors: Filippo CICERI, Serena LUNARDI, Tamara MAES, Cristina MASCARO CRUSAT, Inigo TIRAPU FERNANDEZ DE LA CUEST
  • METHODS TO DETERMINE KDM1A TARGET ENGAGEMENT AND CHEMOPROBES USEFUL THEREFOR
    Publication number: 20190085372
    Abstract: The invention relates to methods to determine KDM1A target engagement and chemoprobes useful therefor. In particular, the invention relates to non-peptidic KDM1A chemoprobes carrying a tag or label that can be used to assess KDM1A target engagement in cells and tissues. These chemoprobes can also be used to identify KDM1A interacting factors and analyze expression levels of KDM1A.
    Type: Application
    Filed: March 16, 2017
    Publication date: March 21, 2019
    Inventors: Elena CARCELLER GONZÁLEZ, Tamara MAES, Cristina MASCARO CRUSAT, Alberto ORTEGA MUN0Z
  • BIOMARKERS ASSOCIATED WITH LSD1 INHIBITORS AND USES THEREOF
    Publication number: 20180284095
    Abstract: The invention relates to biomarkers associated with LSD1 inhibitors and uses thereof to assess target engagement and to follow patient response to treatment. The invention further relates to novel therapeutic uses for LSD1 inhibitors based on said biomarkers.
    Type: Application
    Filed: June 10, 2016
    Publication date: October 4, 2018
    Inventors: Tamara MAES, Cristina MASCARÓ CRUSAT, David ROTLLANT POZO
  • Lysine demethylase inhibitors for myeloproliferative disorders
    Patent number: 9908859
    Abstract: The invention relates to methods and compositions for the treatment or prevention of diseases and disorders associated with myeloproliferative disorders. In particular, the invention relates to an LSD 1 inhibitor for use in treating or preventing Philadelphia chromosome negative myeloproliferative disorders.
    Type: Grant
    Filed: February 20, 2014
    Date of Patent: March 6, 2018
    Assignee: Oryzon Genomics, S.A.
    Inventors: Jonathan Alleman Baker, Julio Castro Palomino, Matthew Colin Thor Fyfe, Tamara Maes, Marc Martinell Pedemonte
  • COMBINATIONS OF LSD1 INHIBITORS FOR USE IN THE TREATMENT OF SOLID TUMORS
    Publication number: 20170281567
    Abstract: The instant invention relates to therapeutic combinations of LSD1 inhibitors and one or more other active pharmaceutical ingredient(s) or pharmaceutically acceptable salts thereof. The combinations are particularly useful for treating neoplastic diseases, such as cancer, particularly small cell lung cancer (SCLC).
    Type: Application
    Filed: March 14, 2017
    Publication date: October 5, 2017
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Mark D. DEMARIO, Tamara MAES, William E. PIERCEALL, Fiona MACK, Serena LUNARDI
  • COMBINATIONS OF LSD1 INHIBITORS FOR THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES
    Publication number: 20170281566
    Abstract: The instant invention relates to combinations of the compound of formula (I) or pharmaceutically acceptable salts thereof with other active pharmaceutical ingredients pharmaceutical compositions comprising them, and their use as medicaments, particularly for the treatment of hematological malignancies.
    Type: Application
    Filed: June 23, 2017
    Publication date: October 5, 2017
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Filippo CICERI, Serena LUNARDI, Tamara MAES, Cristina MASCARÓ CRUSAT, Iñigo TIRAPU FERNÁNDEZ DE LA CUESTA